The 2026 WADA Prohibited List names Thymosin-beta4 and its derivatives e.g. TB-500 under section S2.3. Here is the quoted text, the source PDF, and what it covers.
No human trial has ever tested TB-500 itself. The eleven human studies people cite all used thymosin beta-4, the larger parent protein. Here is the full list.
BPC-157 is on the WADA Prohibited List in Section S2, prohibited at all times for tested athletes. What that means, and why the source is no defense.
BPC-157 is not an FDA-approved drug. What that means, the 2023-2026 compounding timeline, and how “approved,” “scheduled,” and “compounding list” differ.
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is what the human record actually holds.
FDA letter 694608-12102024 cited Xcel Research LLC’s long GLP-1-class product list. Why catalog breadth is not verification — and what to check instead.
SwissChems was named in FDA’s December 10, 2024 warning-letter batch. How to read the letter itself — and how to vet a verification-first alternative.
FDA letter 695607-12102024 cited Summit Research Peptides’ catalog and a company Facebook post. How to audit a successor vendor’s entire footprint.
FDA letter 695156-12102024 told Prime Peptides an RUO disclaimer is no defense. What totality of evidence means and how to audit a vendor in five minutes.
Dated timeline of US research-peptide enforcement, December 2024 to July 2026: FDA warning letters, the Amino Asylum raid, Paradigm pleas and sentencing.